Tesofensine

Also known as: NS2330

Serotonin-norepinephrine-dopamine reuptake inhibitor (triple reuptake inhibitor) that reduces appetite and increases energy expenditure.

Typical dose

250 mcg – 1 mg

Frequency

once daily

Route

Oral

Half-life

9.70833 days

Routes

Oral

Status

Phase III trials: not FDA approved

Benefits

• Significant weight loss
• Appetite suppression
• Increased energy expenditure
• Improved metabolic markers

Dosing

A common research range for Tesofensine is 250 mcg to 1 mg once daily. Oral tablet; start low and titrate. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.

Half-life

Tesofensine has an approximate half-life of 9.70833 days. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.

Storage

Room temperature.

Reported side effects

• Increased heart rate
• Dry mouth
• Insomnia
• Nausea
• Constipation

Contraindications

• Uncontrolled hypertension
• Cardiovascular disease
• MAO inhibitor use

Track Tesofensine with Vial

Vial logs every Tesofensine dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →

This page is for educational and harm-reduction purposes only. Tesofensine is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.